What is Ceftazidime?Ceftazidime belongs to the drug group of antibiotics.
Ceftazidime, also known as ceftazidinum, is an antibiotic. It comes from the third generation of cephalosporins, which in turn are beta-lactam antibiotics, and is used to treat both acute and chronic infections.
The antibiotic prevents the build-up of an intact cell wall of the bacteria and ensures that the wall becomes permeable. In this way, the drug stimulates the dying of the harmful bacteria.
The basis of the action of ceftazidime is the disruption of cell wall synthesis of the bacteria. The germs are thus no longer able to build an intact cell wall. This in turn causes the permeability of the cell wall and has the consequence that the disease-causing bacteria die off.
In this process, ceftazidime is attached to special proteins (proteins) inside the cells. Penicillins can also bind to them. Similar to cephalosporin cefotaxime, ceftazidime is widely used against gram-negative bacteria. In addition, the antibiotic is considered effective against the pathogens Pseudomonas aeruginosa and Burkholderia pseudomallei. The latter is responsible for the tropical disease melioidosis (pseudo-snot). However, unlike cefotaxime, ceftazidime has a weaker effect against Gram-positive bacteria. Thus, its positive effects are limited in streptococci and staphylococci.
Its effect unfolds ceftazidime in the form of powder. This is administered to the patient by injection or infusion. The bioavailability of ceftazidime is around 91 percent. In the blood, the antibiotic binds to ten percent of plasma proteins. The plasma half-life is 90 percent on average. The excretion of ceftazidime from the human body takes place to 90 to 96 percent of the kidneys.
Medical application & use
Ceftazidime can be used against a variety of bacterial infections. These include, in particular, pneumonia occurring in a hospital. Other indications include bacterial meningitis, cystic fibrosis, chronic otitis media associated with pus formation, infections of bones and joints, complicated urinary tract infections, malignant inflammation of the outer ear and severe infections of the skin, muscles and tendons,
Further, ceftazidime is useful in the treatment of sepsis, peritonitis after a blood wash, complicated abdominal infections, and fever due to a lack of neutrophil blood cells. Ceftazidime may also be useful in preventing urinary tract infection by surgical removal of the male prostate (prostate gland) via the urethra.
In addition to adult patients and children, babies can also be treated with ceftazidime. Since ceftazidime is only suitable for the treatment of certain pathogens, some types of infection can not be treated with the antibiotic. The use of cephalosporin is considered justified only if the pathogen is very likely to be classified as sensitive to the remedy.
Risks & Side Effects
As with other antibiotics, there is a risk of side effects from using ceftazidime. However, these do not occur in every patient. Thus, for example, these cephalosporin show significantly fewer allergies than after taking penicillin. Cross-allergies to penicillins are also rare.
Basically, ceftazidime is considered to be well tolerated. However, some patients sometimes suffer from inflammation or obstruction of the blood vessels when the agent is applied via the vein, as well as inflammation and pain when administering an injection of ceftazidime into a muscle.
Furthermore, an excess of platelets and immature blood cells, urticaria-like rash, neutrophilic blood cell deficiency, nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, itching, fever and platelet deficiency are possible. In rare cases, nephritis or even acute kidney failure is imminent.
Ceftazidime should not be administered if the patient is hypersensitive to the active substance or other cephalosporins. The same applies to a previous allergic shock to penicillin, carbapenem or monobactam.
The effects of ceftazidime in pregnancy are limited. Thus, no harmful effects were found in animal experiments. The prescription of ceftazidime to expectant mothers, however, takes place only if there is no other possibility. During lactation, the preparation can be administered because there are no negative effects on the baby to be feared.
When administering ceftazidime, due to harmful interactions, care should be taken not to mix with alkaline solutions with a pH greater than 7.5. In addition, mixing of ceftazidime and aminoglycoside antibiotics should be avoided. By taking these two remedies there is a risk of a negative renal function impairment.